BRIEF—US Galien Foundation honors excellence in scientific innovation

27 October 2017

The Prix Galien USA Committee on Thursday honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 11th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City.

In recognition of the development and discovery of products that improve the human condition, the Prix Galien Awards selection committee recognized winners in three categories: "Best Pharmaceutical Product," "Best Biotechnology Product," and "Best Medical Technology."

The 2017 Prix Galien USA Award Winners

"Best Pharmaceutical Product": AbbVie (NYSE: ABBV) and Genentech (a member of the Swiss Roche [ROG: SIX] group) for Venclexta, (venetoclax), a treatment for people diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion who have received at least one prior treatment.
"Best Biotechnology Product": Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) for Spinraza (nusinersen), a treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
"Best Medical Technology": INSIGHTEC for Exablate Neuro, the first focused ultrasound device approved by the Food and Drug Administration to treat essential tremor patients with non-invasive MR-guided focused ultrasound thalamotomy.

"These products have been developed by remarkable biomedical researchers who have devoted their lives to making a difference," said Bruno Cohen, chairman of the Galien Foundation. "The Committee is honored to be able to provide a forum to recognize these outstanding achievements among a distinguished group of industry peers."